Stocktoria
DiaMedica Therapeutics Inc. DMAC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2008-01-04
DiaMedica Therapeutics Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $24.6M | $19.1M | $13.1M | $7.8M | $8.8M |
| Operating income | -$34.4M | -$26.7M | -$21.3M | -$14.0M | -$13.6M |
| Income tax | $28,000 | $30,000 | $43,000 | $28,000 | $28,000 |
| Net income | -$32.8M | -$24.4M | -$19.4M | -$13.7M | -$13.6M |
| Operating cash flow | -$29.1M | -$22.1M | -$18.7M | -$11.5M | -$12.3M |
| Free cash flow | -$29.1M | -$22.1M | -$18.8M | -$11.6M | -$12.3M |
| Cash & equivalents | $15.6M | $3.0M | $4.5M | $4.7M | $4.7M |
| Total assets | $61.4M | $46.3M | $54.2M | $34.4M | $45.6M |
| Shareholders' equity | $56.1M | $40.7M | $51.1M | $31.8M | $44.0M |
Source: SEC EDGAR filings · CIK 0001401040 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.